Scott earned his Ph.D. in Pharmacology from Georgetown University in 2003. Prior to graduate school he worked in pharmacokinetics at Glaxo Inc and Bayer, and as a biology scientist at Nobex Inc evaluating oral peptide delivery systems. Following graduate school he was hired at Abbott Labs (now AbbVie Inc) in the in vivo pharmacology deparment, where he spent much of his time testing Bcl-2 inhibitor compounds including venetoclax. In 2011, Scott was transferred to late stage Discovery where he has worked on a variety of programs including epigenetic targets, cancer metabolism targets and phenotypic screening.
Scott has worked in almost all fields of Discovery translational science at one point in his career including target validation, characterization and IND transfer, pharmacokinetics, pharmaceutics, and non-GLP toxicology, in the fields of oncology and metabolic diseases.
At Recursion Scott hopes to be a part of changing the way medicines are identified, processed and delivered to patients. Phenotypic screening in rare disease space has the potential to identify novel pathways in disease and bring novel treatments to unmet needs.
In his spare time, Scott is an avid cinephile and bibliophile, loves to cook and spend time with his family.
Are you Recursion ready?
Join our passionate, innovative team—and help us realize our goal of 100 treatments by 2025.